The aspirin can have a “great effect” in stopping the return of colon and rectum cancer, and you find the study | Medical research
The daily dose of aspirin can significantly reduce the risk of some colon and rectal cancers after surgery, according to a large experience in the preventive effects of daily analgesics.
The Swedish researchers found that people who took a low daily dose of aspirin after removing their tumor were likely half of the cancer over the next three years of patients who took an imaginary drug.
The experiment included cancer patients whose tumors carried specific genetic mutations that made them vulnerable to the anti -cancer aspirin properties. About 40 % of colon and rectal cancer patients have such mutations.
“I think this will change the clinical practice,” said Professor Anna Marteling, who led Alascca trial At the Carolinska Institute in Stockholm. “If you have these mutations, the risk of cancer has been reduced by more than 50 %. It is a major effect.”
Nearly 2 million people are diagnosed with colon and rectal cancer every year around the world, with more than 40,000 cases in the United Kingdom. Many removed their tumors, but despite the progress of chemotherapy, radiotherapy and surgery, cancer can return if the cells are left behind.
Bowel cancer rates are increased all over the world in people under the age of 50, and although the reasons are unclear, scientists suspect that unwanted food, obesity, lack of physical activity and toxins produced by intestinal bacteria.
Previous experiments have shown that aspirin can help prevent colon and rectal cancer in people with a high risk due to genetic conditions such as Lynch syndrome. But it was not clear whether the drug was reduced from the chances of repeated cancer after surgery.
Martling and her colleagues have recruited more than 3,500 patients with tumors and rectal in hospitals in Sweden, Norway, Denmark and Finland. Genetic tests on 2,980 patients found that 1,103, or 37 %, had mutations in genes that constitute a biological path called PI3K, which is involved in colon and rectum cancer.
Patients with mutations were randomly assigned to get 160 mg aspirin per day or fake for three years after surgery. The experiment showed that those who were on aspirin were 55 % less likely to return to cancer than those in the imaginary medicine.
The drug appears to protect against cancer by relieving inflammation, interfering with the PI3K path, and relieves doll platelet activity, which can surround cancer cells and effectively hide them from the patient’s immune system.
Marting said that the results confirmed the need to take genetic tests on all colon and rectum cancers so that patients who stood to benefit from aspirin can be given the drug. She said: “It is a very extensive, inexpensive drug,” she said.
Aspirin was on the market for more than a century, but long -term drug intake still had risks. In experiment, four patients had “severe negative events” that are likely to be linked to aspirin, including allergic reaction, intestinal bleeding and bleeding on the brain. Four patients died across the arms of the experiment, with one death that may cause aspirin. Details are published in New England Magazine for Medicine.
“Preventing cancer saves lives, and finding new ways to do this is essential to our efforts to overcome cancer. There is increasing evidence that in certain groups of people, low -dose aspirin can provide protection from intestinal cancer,” said Dr. Catherine Elliot, Director of Research at Cancer Research UK.
“The CAPP3 experience by the CANCER Research in the United Kingdom showed a similar effect in people with lynch syndrome, a legacy condition that increases the risk of intestine and other types of cancer.
“We need larger and high -quality studies such as CAPP3 and this last research to confirm who will benefit more than taking aspirin to help live a longer life, better, free of fear of cancer.”